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Abstract 
Pediatric adamantinomatous craniopharyngioma (ACP) is a highly solid and cystic tumor, often 
causing substantial damage to critical neuroendocrine structures such as the hypothalamus, 
pituitary gland, and optic apparatus. Paracrine signaling mechanisms driving tumor behavior 
have been hypothesized, with IL-6R overexpression identified as a potential therapeutic target. 
To identify potential novel therapies, we characterized inflammatory and immunomodulatory 
factors in ACP cyst fluid and solid tumor components.  Cytometric bead analysis revealed a 
highly pro-inflammatory cytokine pattern in fluid from ACP compared to fluids from another 
cystic pediatric brain tumor, pilocytic astrocytoma (PA). Cytokines and chemokines with 
particularly elevated concentrations in ACPs were IL-6, CXCL1 (GRO), CXCL8 (IL-8) and the 
immunosuppressive cytokine IL-10. These data were concordant with solid tumor compartment 
transcriptomic data from a larger cohort of ACPs, other pediatric brain tumors and normal brain. 
The majority of receptors for these cytokines and chemokines were also over-expressed in ACPs. 
In addition to IL-10, the established immunosuppressive factor IDO-1 was overexpressed by 
ACPs at the mRNA and protein levels. These data indicate that ACP cyst fluids and solid tumor 
components are characterized by an inflammatory cytokine and chemokine expression pattern. 
Further study regarding selective cytokine blockade may inform novel therapeutic interventions.  
 
Keywords: Adamantinomatous Craniopharyngioma; Craniopharyngioma Cyst; Cytokine; 
Inflammatory; Immunomodulation; IL-6 
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Introduction: 
 
Adamantinomatous Craniopharyngioma (ACPs) is an uncommon brain neoplasm accounting for 
approximately 4% of pediatric brain tumors(1). It is associated with significant neurological and 
endocrine morbidity despite being a World Health Organization (WHO) grade I tumor. The most 
severe damage occurs in patients who suffer hypothalamic injury(2), which may occur as a result 
of finger-like tumor infiltration(3) or therapeutic efforts to surgically remove the tumor(4). ACP 
is among a small number of pediatric brain tumors characterized by the combination of cystic 
and solid tumor components and the other most common such entity is Pilocytic Astrocytoma 
(PA). ACP cysts often exert substantial mass effect on critical structures, including the 
hypothalamus, optic pathway, Circle of Willis vessels, and the third ventricle. This phenomenon, 
combined with the slow growth of solid components of ACP, has prompted efforts to control this 
tumor using cyst-directed therapies(5-7). Most cyst-directed therapies require direct surgical 
access, and may be associated with significant complications(5,7).  
 
Systemically administered anti-tumor therapies for ACP could control cyst expansion without 
the risk associated with operative intra-cystic catheter placement and subsequent care, or the 
need for repeated transcutaneous device access to deliver therapy. In addition, reduction of cyst 
volume might decrease the risk of hypothalamic injury associated with radical resection of 
ACP(8), by facilitating separation of the cyst wall from the hypothalamus. 
 
Emerging evidence suggests that ACP pathology may involve inflammatory mechanisms. In 
2004, Mori and colleagues described elevated IL-6 expression in ACP(9). Subsequent analyses 
of ACP cyst fluid demonstrated inflammatory activity(6,10). In a recent study of pediatric ACP, 
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our laboratory described elevated levels of mRNA transcripts associated with IL-6R in ACP 
tumor tissue, when compared to other pediatric brain tumors and normal tissue(11). In the 
clinical setting, a review of intra-cystic therapies in childhood ACP concluded that interferon 
(IFN) has the highest benefit to risk ratio, versus Bleomycin or radioisotopes(12). Yueng and 
colleagues(13) described 5 children with recurrent ACP managed using subcutaneously 
administered pegylated IFN-α-2b. Further support for the assertion that ACP growth uses 
paracrine mediators comes from genetic tracing experiments using a novel mouse model(14,15). 
This work additionally demonstrated 2-fold enrichment of Cxcl1, 30-fold enrichment of Cxcl2, 
and 29-fold enrichment of Cxcl3 gene expression in clusters of β-catenin mutated cells (the only 
known genetic mutation in ACP(16)), relative to non-cluster regions(15). To date, however, there 
has been no detailed description of immunomodulatory pathways in ACP.  
 
The clinical relevance of investigating inflammatory drivers in ACP is bolstered by the 
successful utilization of directed therapies against inflammatory mediators in other tumor types 
and other diseases in both adults and children, notably systemic juvenile idiopathic arthritis and 
Castleman’s disease(17,18). Monoclonal antibodies directed against human IL-6R (tocilizumab) 
and IL-6 (siltuximab) both have regulatory approval in the United States and Europe. Small 
molecule antagonists of other pro-inflammatory cytokines, such as CXCL1 and CXCL8 (IL-8) 
have been suggested to have efficacy in preclinical models of human cancers(19), and are 
generally well tolerated in humans(20).  
 
We sought to determine whether comprehensive analysis of cytokine and chemokine levels in 
pediatric ACP cyst fluids and solid tumor tissue would implicate inflammatory mechanisms of 
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tumor pathogenesis, and whether these mechanisms may be susceptible to available directed 
therapies.   
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Materials and Methods 
 
Cytometric Bead Analysis  
Cyst fluids from 5 histologically confirmed pediatric ACPs and 5 pediatric PAs were analyzed 
using multiplexed cytometric bead analysis (Milliplex Map kit; Millipore, Temecula, CA) to 
measure the concentration of 24 cytokines and 11 chomokines (listed in Supplementary Table 1) 
per manufacturer’s instructions. The specimens were obtained with IRB approval (COMIRB 14-
0426 and 95-500). ACP samples were obtained through the Advancing Treatment for Pediatric 
Craniopharyngioma Consortium and PAs were from the clinical service at Children’s Hospital 
Colorado. ACPs were compared to PAs as another histologically benign pediatric brain tumor 
that is characterized by cyst formation. For comparative studies, measured analyte concentrations 
were transformed from raw values to log2 to better express biological relationships.  
Transcriptomic Analysis 
Transcriptome assays were completed using 23 ACP samples, processed as previously 
described(11). Three of these specimens were also analyzed in the above cyst fluid analysis. 
Samples were collected at surgery and snap frozen. The proportion of tumor tissue and of brain 
tissue with glial reaction was estimated histologically. The reference panel included 148 samples 
of primary tumors and non-neoplastic (“normal”) cerebral tissues. This included 10 atypical 
teratoid/rhabdoid tumors (AT/RT), 29 ependymomas (EPN), 10 glioblastomas (GBM), 15 
medulloblastomas (MED), 10 pilocytic astrocytomas (PA), 11 embryonal tumors (EmT), 23 
specimens of non-neoplastic pituitary and 27 specimens of non-neoplastic cerebrum. Tumors 
were classified according to the WHO international histological tumor classification. Non-
neoplastic brain samples were obtained during epilepsy surgery or autopsy at Children’s Hospital 
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Colorado.  
Tumor samples were analyzed using the Human Genome U133plus2 Array (Affymetrix) 
platform as previously described(11,21). Data analysis was performed in R (http://www.r-
project.org), using publicly available packages (http://www.bioconductor.org). Microarray .CEL 
datafiles were background corrected and normalized using the guanine cytosine robust multi-
array average (gcRMA) algorithm resulting in log2 expression values(22). To reduce error 
associated with multiple testing, a filtered list was created containing the highest expressed probe 
across all samples for each gene with multiple probesets. This list was further filtered to remove 
probe sets that were expressed below a threshold level denoting absence of expression in any 
sample. These data are available in the National Center for Biotechnology Information Gene 
Expression Omnibus (GEO) database(23) and are publicly accessible through GEO Series 
accession number GSE94349 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE94349).  
Transcripts corresponding to cytokine and chemokine analytes included on the 35-plex 
cytometric bead assay, cognate receptors of key cytokines and chemokines and established 
soluble immunosuppressive factors were identified and extracted from the microarray dataset for 
further analysis (Supplementary Tables 1-3).  Genes with significant differential expression were 
defined as those in ACP compared to other tissues by pair-wise comparisons (p <0.05) 
 
Immunohistochemistry  
Immunohistochemistry assessing the presence of IL-6Rα was performed on archival paraffin 
embedded sections of human ACPs and normal non-cerebral tissues from the Childhood Cancer 
and Leukaemia Group and Department of Histopathology at Great Ormond Street Hospital for 
Children using mouse monoclonal H7 anti-IL-6Rα antibody (Santa Cruz Biotechnologies) at a 
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dilution of 1:300 on the Leica Bond-Max automated immunostainer.   
Immunohistochemistry assessing the presence of IDO-1 was completed in specimens of ACP 
and normal brain tissue using the 4.16H1 anti-IDO-1 antibody, as previously described (gift from 
Dr. Benoit Van den Eynde, Ludwig Cancer Inst. for Cancer Research, Brussels, Belgium). The 
antibody was diluted at 1:1000 after DAKO pH9 antigen retrieval(24). 
 
Immunofluorescence 
Immunostaining for pSTAT3 and in situ hybridisation for CXCR2 were performed on archival 
paraffin embedded sections of human ACPs from the Department of Histopathology at Great 
Ormond Street Hospital for Children. Primary antibodies (Rabbit anti-pSTAT3 at 1:200 and 
Mouse anti-β-catenin at 1:300) were incubated together overnight at 4oC. The next day after 
washing the primaries with PBS (0.1% Triton-X), we incubated the slides with Goat anti-rabbit 
biotinylated antibody at 1:250 dilution for 1 hour at room temperature. After washing, the slides 
were incubated 1 hour at room temperature with a Streptavidin-AlexaFluor 555 conjugate (1:500 
dilution) as well as Goat anti-mouse AlexaFluor 488 (1:250 dilution). pSTAT3 was thereby 
labelled with S555, and β-catenin with AlexaFluor 488. Sections were controlled for 
autofluorescence using Sudan Black. They were counterstained with DAPI and mounted. 
 
In Situ Hybridization 
In situ hybridization on paraffin sections was performed as previously described(25). The 
CXCR2 probe was generated by amplification of a 633bp fragment from genomic DNA, using 
forward and reverse primers: 5’- GCCTCGAGATAGTGGCATCCTGCTACTG -3’ and 5’-
GCGAATTCCTGATCAAGCCATGTATAGC- 3’, respectively. PCR product was cloned into 
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the pBlueScript SK vector (XhoI 5′, EcoRI 3′) and antisense riboprobes synthesized with T3 
RNA Polymerase. 
 
Statistical analyses  
Statistical analyses were performed using R bioinformatics, Prism (GraphPad), and Excel 
(Microsoft) software. For all tests, statistical significance was defined as P < 0.05.  
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Results 
 
ACP cyst fluid is characterized by high levels of cytokines and chemokines 
Cyst formation is associated with multiple pediatric brain tumors, most commonly ACPs and 
PAs, but also occasionally EPNs, Gangliogliomas and high-grade neoplasms, among others. In 
the present study, cytokine and chemokine levels in ACP cysts were only compared to PA cyst 
levels due to the number of samples available.  
 
Of the 35 analytes measured by the multiplex assay, 16 chemo-/cytokines were detected at 
significantly (p<0.05) higher levels in fluid from ACPs (n=5) versus PAs (n=5). Six cytokines 
demonstrated differential levels at a significance level of p<0.001, and 4 at a significance level of 
<0.0001 (figure 1). These included IL-6, IL-10, CXCL8 (IL-8), and CXCL1 (GRO). The full list 
of analyte levels in ACPs compared to PAs is in Supplementary Table 1. 
 
IL-6 levels showed the greatest statistical difference between the 2 tumor types (ACP/PA ratio 
7.64, p=5.97 x10-8). The mean concentration in ACP cyst fluids was 8.9 ng/ml. CXCL1 (GRO) 
demonstrated the greatest absolute concentration difference (ACP/PA ratio 1311.3, p=0.000285) 
with a mean concentration in ACPs of 8.6 ng/ml. CXCL8 (IL-8), which shares receptor CXCR2 
with CXCL1, also demonstrated significantly higher levels in ACPs (ACP/PA ratio 4.18, 
p=9.44x10-5) with a mean concentration of 6.1 ng/ml. IL-10 levels were higher in ACPs 
compared to PAs (ACP/PA ratio 15.0, p= 6.79x10-5) at a concentration of 221 pg/ml in ACPs. 
Each of these cytokines: IL-6, IL-10, CXCL1, and CXCL8 and/or their receptors, has 1 or more 
clinically available medications that target their function (Table 1).  
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Transcript expression of several cytokines and chemokines is elevated in the solid tumor 
component of ACPs. 
Given the potential for rapid clinical translation, we further investigated these molecules by 
examination of gene expression levels in the solid tumor component of ACPs. We extracted 
cytokine and chemokine data from a transcriptomic microarray dataset containing a large cohort 
of surgical specimens of ACP, PA and a variety of other pediatric brain tumors as well as normal 
brain tissue(11). This furthered our study of these molecules in ACPs by (i) validating and 
expanding the findings of our cytometric bead analysis, (ii) exploring the relationship between 
the presence of key cytokines and chemokines in ACP cyst fluid and corresponding solid ACP 
tumor components, and (iii) examining expression patterns of associated cytokine and 
chemokine receptors and key soluble immunosuppressive factors.  
 
Pro-inflammatory Mediators 
IL-6 and IL-6 receptors 
IL-6 transcript levels were, as anticipated from cytometric bead analysis, higher in solid tumor 
components of ACPs than PAs (ratio=3.25; p=0.018). Furthermore, transcript expression was 
higher in ACP tumors than any other brain tumor or normal brain tissues (figure 2a). This 
difference was statistically significant (p<0.05) when compared to AT/RTs, MEDs, EmTs, and 
normal brain samples, but not when compared to EPNs, GBMs, GGs or normal pituitaries. 
The IL-6 receptor is a heterodimeric complex of two proteins, IL-6R and IL-6ST (gp130). 
Transcript levels of these components in ACP solid tumors were examined. IL-6R transcript 
expression was statistically significantly higher in ACPs relative to any other tumor/tissue type 
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(figure 2b) except GGs. IL-6ST was present at similar levels in all tumor/tissue types, including 
ACPs (figure 2c). Details of cytokine and chemokine receptor transcript probesets are in 
Supplementary Table 2.  
 
We further examined the pattern of IL6-Rα expression at the protein level in ACP tumor sections 
by immunohistochemistry. Using a monoclonal antibody for IL6-Rα we identified 
immunoreactivity that was predominantly limited to the stellate reticulum and occasional 
reactive cells, and was not present in the palisading epithelium(figure 2d-f). As expected, there 
was light immunoreactivity in control tissues including human kidney, palatine tonsil and 
placenta (data not shown).   
 
IL-6 drives phosphorylation and activation of STAT3. Persistent signaling through this pathway 
in cancer can result in a chronic inflammatory phenotype and suppression of antitumor 
immunity(26). To determine the activation status of STAT3 in ACPs, we performed 
immunofluorescence for phospho-STAT3 in ACP tumor sections. Phospho-STAT3 expression, 
indicating pathway activation, was similarly observed in tumor cells and some surrounding areas 
of reactive tissue (figure 2g-i) consistent with the IL6-Rα immunostaining. 
 
CXCL1, IL-8 and CXCR2 
CXCL1 (GRO-α) transcript levels were significantly higher in ACP solid tumors than in PAs 
(ratio=19.7; p=3.61x10-9), in concordance with its overexpression in ACP cyst fluids (figure 3a). 
CXCL1 was significantly higher in ACP tumors than any other brain tumor or normal brain 
tissue type. Similar to CXCL1, levels of IL-8 (CXCL8) transcript were higher in ACPs than in 
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PAs, consistent with overexpression of IL-8 protein in cyst fluid. IL-8 transcript levels were 
higher in ACP than other tissues types examined, apart from EPNs and GBMs (figure 3b). 
CXCL1 and IL-8 both bind the chemokine receptor CXCR2. Transcript levels of CXCR2 were 
higher in ACP tumors than in any other tissue type, except PAs, however this difference only 
reached statistical significance when ACPs were compared to AT/RTs, MEDs and normal tissues 
(figure 3c). 
To investigate the distribution of CXCR2 within the ACP tumor microenvironment, we 
performed in-situ hybridization (ISH) for CXCR2 in ACP tissue sections. There was strong 
hybridization to CXCR2 mRNA in the epithelial compartments of the tumor and less in reactive 
glial areas (figure 3b-d). Collectively, these findings suggest that the effects of pro-inflammatory 
factors CXCL1 and IL-8 are predominantly focused on the epithelial component of ACPs. 
 
Immunosuppressive Factors 
IL-10, IL10RA, IL10RB 
IL-10 was expressed at relatively high levels in ACP cyst fluids. This cytokine is significant due 
to its well-established immunosuppressive role in the brain and in systemic tumor models(27,28). 
IL-10 transcript expression in ACP solid tumors was marginally higher than in any other tumor 
type, but this difference reached statistical significance only when ACPs were compared to 
EmTs (figure 3b). This is likely due to transcript levels for IL-10, as is the case for many other 
interleukin transcripts, being detected at very low levels. The uniformly low levels seen in all 
tumor samples in this dataset make comparisons with protein levels, as measured in 
corresponding cyst fluid components of the same tumor, less reliable than for more abundant 
transcripts.   
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The IL-10 receptor is a heterodimer of proteins IL-10RA and IL-10RB. Levels of IL-10RA and 
IL-10RB transcript were both higher in ACP solid tumors than in any other brain tumor or 
normal tissue examined, with this difference reaching statistical significance for all comparisons 
except ACPs relative to PAs and GGs regarding levels of IL-10RA (figure 3b).  
 
IDO-1 
Given that IL-10 is a well-established soluble immunosuppressive factor in brain and other 
tumor types, we examined the transcript expression of a panel of other established soluble 
immunosuppressive factors in ACP solid tumors(29) (see Supplementary Table 3). This analysis 
identified significantly elevated levels of IDO-1 mRNA in ACPs relative to any other tissue type 
(figure 4a, fold change 9.43 versus all other tumor types combined, p=1.4x10-28). As IDO-1 is a 
therapeutic target undergoing early phase clinical trials, we examined its expression at the 
protein level in ACP tumor sections by immunohistochemistry. Using the monoclonal antibody 
4.16H1(24) we identified immunopositivity of superficial epithelial cells in specimens of ACP 
(figure 4c-f) while there is no immunoreactivity in specimens of normal frontal lobe (figure 4b).  
Of the other candidate soluble immunosuppressive factors, only galectin-1 transcript levels were 
significantly elevated in ACP tumors relative to other tissues (fold change 3.27, p=2.12x10-7). 
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Discussion 
Children afflicted with ACPs have not yet benefited from biologically guided antitumor 
therapies. As a histologically benign and heterogeneous tumor, ACPs present challenges for 
biological investigations, especially given the paucity of experimental models in particular the 
lack of any established ACP cell lines.. The cystic component of ACPs can present unique 
clinical challenges, such as rapid enlargement and unpredictable response to radiation therapy.  
This work presents novel insights regarding the biological characteristics of ACP cyst fluid and 
tumor tissue, indicating that immune system modulators may play a critical role in tumor 
behavior. As with systemic inflammatory processes, it is possible that high levels of chemokines 
drive fluid secretion in a process that allows for greater infiltration of immune cells. Therapies 
that diminish or reverse this process may offer the opportunity to control the local effect of ACP 
without, or in conjunction with, surgical and/or radiation therapy, but further preclinical 
investigation is needed.   
 
This work is also the first to describe immunosuppressive factors, such as IL-10 and IDO-1, in 
ACPs. Our findings build on previous work in human and mouse models(11,15) indicating that 
pro-inflammatory mediators such as IL-6, CXCL1 and CXCL8 are present at unique levels in 
ACPs, both at protein and transcript levels. The consistency of our findings across different 
compartments of ACP tissue (cyst fluid and tumor), and within human and animal contexts, 
strengthens the findings.  
 
The only confirmed genetic alteration in ACP is a mutation lies within exon 3 of the CNTTB1 
gene, resulting in accumulation of β-Catenin.  While pro-inflammatory mediators have been 
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identified in clusters of β-catenin mutated cells in mouse ACPs(15), the cellular origin of these 
mediators in human tumors remains unconfirmed. Mechanistic links between β-catenin 
mutations and inflammatory or immunomodulatory mediators in human ACP have also yet to be 
defined, and should be the focus of future studies. A number of studies in other tumors, including 
colon cancer, which is also associated with β-catenin mutation, have identified stimulation of the 
key inflammatory mediator NF-κB in response to upregulated Wnt/β-catenin activation(30). 
Oncogenic β-catenin has also been shown to have a significant inflammatory impact on the 
crosstalk of tumor cells with tumor associated immune cells in colon cancer(31). Such crosstalk, 
mediated by cytokines and chemokines, may occur between tumor cells, associated immune cells 
and reactive glia in ACP.  
 
IL-6 
Concerning rapid translation into clinical application, our findings regarding IL-6 may be the 
most immediately relevant. The above referenced animal models of ACP(14,32,33) combined 
with the clinical success of therapeutic monoclonal antibodies against IL-6R and IL-6, such as 
Tocilizumab and Siltuximab in other clinical contexts (17,18) offers the opportunity to explore 
IL-6 activity in preclinical models. Evidence of pituitary origin of ACPs(15) and a preliminary 
report using systemically administered IFN-α-2b(13) support the notion that ACPs do not dwell 
within an immunoprivileged space, which may allow these large molecules to affect ACP tissues 
following systemic administration.  
 
We identified uniquely elevated levels of IL-6 protein in ACP cyst fluids; and of IL-6R and, to a 
lesser extent, IL-6 transcripts in tumor tissue. Although levels of IL-6ST (gp130) transcripts were 
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not uniquely elevated in ACP, the presence of pSTAT3 is consistent with IL-6 active signaling. 
These findings taken together are consistent with the assertion that IL-6 plays a critical role in 
the pathogenesis of ACPs. As a ubiquitous cytokine that demonstrates context-dependent 
inflammatory activity(34,35), IL-6 has myriad effects in oncologic systems, including brain 
tumors such as EPNs(36) and GBMs(37), both of which demonstrated high levels of IL-6 
transcripts in our analysis. While this work suggests that IL-6 participates in ACP pathogenesis, 
its precise role and intratumoral cell of origin remain unknown. The observation that IL-6R 
expression and STAT3 phosphorylation are observed in the stellate reticulum and, to a much 
lesser extent, in the adjacent reactive glial regions, suggest that the effects of IL-6 may be 
widespread throughout the tumor microenvironment. In the context of posterior fossa EPN, 
subgroup A, IL-6 induces the expression of CXCL8 (IL-8) from cells of myeloid lineage through 
STAT3, in a process that can be reversed using the IL-6R antibody, tocilizumab(36). 
Interestingly, herein we also describe high levels of IL-8 (CXCL8) in ACP cyst fluids and tissues 
(discussed further below). While IL-6 has been demonstrated to mediate cell proliferative 
activity through a paracrine mechanism, it also contributes to autocrine mediated oncogene-
induced cellular senescence(35). 
 
Other ACP-associated Pro-inflammatory Mediators 
CXCL1 (GRO) is a soluble growth factor that, like IL-8 (CXCL8), signals through CXCR2. 
Each of these chemokines is tightly linked with neutrophil chemoattraction and activation, and 
has been extensively investigated in the context of inflammatory airway diseases. As with IL-6, 
CXCL1 is associated with tumor pathogenesis in multiple contexts(19,38,39), but their roles in 
ACPs remain to be described. Interestingly, IL-8 has been shown to induce tumor invasive 
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behavior through a mechanism that includes matrix metallopeptidase-9 (MMP-9) in normal 
tissue and neoplasia models(40,41). Our findings, combined with previous data(11) demonstrate 
elevations in both IL-8 and MMP-9 in ACPs, potentially implying a mechanism of hypothalamic 
tumor invasion. The finding that CXCR2 expression is largely restricted to epithelial tumor 
regions in ACPs suggest that IL-8 and CXCL1 exert a targeted effect in tumor pathogenesis. This 
may have implications for the efficacy of therapeutically targeting IL-8/CXCL1/CXCR2 versus 
IL-6 and/or it’s receptors.  
 
The orally active combined small molecule inhibitor of the CXCR1 and CXCR2 receptors, 
Navarixin (SCH527123/MK7123), inhibited CXCL1 and IL-8 mediated neutrophil migration in 
humans(20). Preclinical studies have further demonstrated antitumor activity of SCH527123 in 
models of human cancer (19). Selective CXCR2 antagonists that have demonstrated acceptable 
risk profiles in humans include Danirixin(42) and AZD5069(43).  
 
Immunosuppressive Factors    
This is the first work to demonstrate elevated levels of immunosuppressive factors in ACPs. 
Specifically, we present evidence of IL-10 and IDO-1 expression at both the protein and gene 
expression levels. The presence of these molecules may facilitate tumor escape from host 
immune surveillance, or represent a response to the pro-inflammatory conditions described 
above. Given the recent clinical successes of therapies that target immunosuppressive factors, 
such as CTLA-4, in other tumors, identification of immunosuppressive mechanisms in ACPs 
may allow us to select similarly effective therapies. 
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IL-10, formerly known as Cytokine Synthesis Inhibitory Factor, is recognized as a pleiotropic 
cytokine with primarily immunosuppressive effects(29,44), although it has also been 
demonstrated to play an immunostimulatory role in certain contexts(27,45,46). It is produced by 
a host of cell types, including monocytes/macrophages, B cells, NK cells, and T cells(47) In 
experimental systems, IL-10 effectively limits IL-6 and IL-8 production at the transcriptional 
level, in addition to downregulating its own mRNA production in an autoregulatory manner(48). 
As with IL-6ST (gp130), the Rβ subunit of the IL-10 receptor serves as a component in a 
multitude of cytokine receptor complexes(49). However, there is evidence that IL-10Rα 
expression plays a critical role in the balance of IL-6 and IL-10 driven signaling from T 
cells(50). Further studies regarding the cells of origin of the cytokines in ACPs may help 
determine whether a disordered balance of these 2 cascades (IL-6 versus IL-10 mediated) 
contributes to a pathological inflammatory environment. Although clinical trials of recombinant 
human IL-10 in autoimmune diseases have demonstrated mixed degrees of therapeutic efficacy, 
there have not been concerns with regard to medication safety(51).  
 
IDO-1 is a well-described immunosuppressive metabolic enzyme that is believed to play roles in 
immune tolerance and defense against pathogens. It is commonly expressed by antigen 
presenting cells in the human gut, thymus, lymph nodes, lung and placenta(24,29). The enzyme 
works through the oxidation of tryptophan to kynurenine, thereby restraining the proliferation 
and activation of both innate and adaptive immune actors, including NK cells and T-
lymphocytes. It is believed to mediate a locally immunosuppressive milieu(24). IDO-1 may also 
suppress intratumoral IFN levels. This mechanism may underlie the pilot findings of Yeung and 
colleagues(13), who described the successful treatment of 5 children with multiply recurrent 
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ACPs using pegylated IFN-α-2b, which may overcome IDO-1 mediated suppression. Our data 
indicate that levels of IDO-1 transcripts are uniquely elevated in ACPs, and that the protein is 
localized to the superficial epithelium of the tumor tissue. Localization of IDO-1 in epithelial 
cells is consistent with previous findings by both Sedlmayr and Théate, who identified IDO-1 
expression in squamous epithelium of the human female reproductive tract (24,52). Presently, 
orally available direct inhibitors of IDO-1, Epacadostat (INCB24360) and GDC-0919 are in 
multiple clinical trials for adult malignancies (https://clinicaltrials.gov/ct2/results?term=IDO-
1&type=&rslt=&recr=Open&age_v=&gndr=&cond=&intr=&titles=&outc=&spons=&lead=&id
=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&rcv_s=&rcv_e=&lup_s=&lup
_e=).  
 
The Inflammatory Milieu in Adamantinomatous Craniopharyngiomas 
While this work demonstrates that inflammatory processes are highly active in pediatric ACP, 
the nature and balance of pro-inflammatory and immunomodulatory activity require further 
exploration before safe and effective anti-tumor regimens can be introduced into human trials. 
For example, the context-dependent action of cytokines such as IL-6 and IL-10 prevents us from 
elucidating their roles in ACP at this time. Further insight regarding the cells of origin of the 
inflammatory actors that we have identified may allow inferences regarding their activity, 
thereby informing preclinical trials that could include directed therapeutics, such as those 
described above.   
 
For example, elevated IL-6 expression may represent a mechanism of mitogenesis. Alternatively, 
IL-6 may be serving to limit tumor stem cell growth. The presence of immunomodulators such as 
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IDO-1 and IL-10 may facilitate tumor cell escape from a previous immunoediting equilibrium, or 
reflect inadequate control of tumor-induced inflammation, mediated by IL-6, CXCL1 and IL-8. 
In addition, the link between IL-8 and MMP-9 may help explain the mechanism through which 
ACP invades the hypothalamus, eliciting brisk reactive astrocytosis and Rosenthal fiber 
formation, a characteristic that is responsible for a considerable proportion of ACP-associated 
morbidity.  
 
Efficient translation of these findings may be facilitated by the current availability of 
medications that target these pathways in combination with the recent development of mouse 
models of ACP(14,32).  
 
Conclusions 
This work provides novel insights regarding the activity of inflammatory mediators in pediatric 
ACP cyst fluids and corresponding tumor tissue. Through analysis on the transcript and protein 
levels, we describe elevated levels of IL-6, CXCL1, IL-8, IL-10 and their receptors in ACPs, 
relative to other pediatric brain tumors and normal cerebral tissue. These findings are also 
consistent with previous data from an embryonic mouse model of ACP. We additionally describe 
high levels of the immunomodulatory enzyme IDO-1. These findings, taken within the context of 
recent advances in ACP animal models and successful directed therapies in humans, provide a 
robust platform for multiple preclinical studies, with the potential for rapid translation towards 
novel directed therapies against pediatric ACPs. 
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Figure Captions 
Figure 1: Differential Levels of Cytokines and Chemokines in ACPs relative to PAs based on 
Cytometric Bead Analysis of Tumor Cyst Fluid. Significant differences in protein levels were 
identified in 16 of 41 analytes tested. The greatest statistical differences between ACP and PA 
levels were identified in IL-6, IL-10, IL-8 and CXCL1 
 
Figure 2: (a-c) Gene expression of IL-6 and IL-6 receptor components in ACPs and a panel of 
148 other brain tumors and normal brain specimens including Pilocytic Astrocytomas (PAs), 
Atypical Teratoid/Rhabdoid Tumors (AT/RTs), Ependymomas (EPNs), Glioblastomas (GBMs), 
Gangliogliomas (GGs), Medulloblastomas (MEDs), and Embryonal Tumors (EmTs). Values are 
expressed as log2 gene expression. Horizontal red bars represent the mean, and error bars 
represent standard error of the mean (SEM). (d-f) Immunohistochemical stains of human ACP 
tissues using anti-IL-6Rα antibody (Santa Cruz). (d, 10x magnification) ACP tissue demonstrates 
strong staining throughout the stellate reticulum, with sparse staining in the adjacent reactive 
gliotic region and epithelial regions. (e, 20x magnification) Redemonstration of IL-6Rα staining 
in the stellate reticulum. (f, 10x magnification) Sparse IL-6Rα staining in the reactive glial tumor 
region adjacent to the epithelium and stellate reticulum. (g-i) Double immunofluorescence 
staining revealing the expression of pSTAT3 (red) and β-catenin (green) in both epithelial and 
surrounding glial tumor components. Labels in panel e include whorl-like epithelial regions 
(EW); palisading epithelium (PE); reactive/glial supporting tissue (GS). Cell nuclei are 
counterstained with DAPI (blue in panel f).  
 
Figure 3: Gene expression of (a) CXCL1, IL-8 and CXCR2 in ACPs and a panel of 148 other 
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brain tumors and normal brain specimens including Pilocytic Astrocytomas (PAs), Atypical 
Teratoid/Rhabdoid Tumors (AT/RTs), Ependymomas (EPNs), Glioblastomas (GBMs), 
Gangliogliomas (GGs), Medulloblastomas (MEDs), and Embryonal Tumors (EmTs). Values are 
expressed as log2 gene expression. Horizontal red bars represent the mean, and error bars 
represent standard error of the mean (SEM). (b-d) in situ hybridization in histological sections of 
human ACPs demonstrating the expression of CXCR2 throughout the tumor tissue. Panel b 
demonstrates a low magnification view. Panel c demonstrates a high magnification view with 
expression within an epithelial whorl (EW) as well as within the stellate reticulum (SR). Panel d 
demonstrates intermittent expression within the reactive/glial supporting tissue (GS) as well as 
palisading epithelium (PE).  
 
 
Figure 4: Gene expression of IL-10 and IL-10 receptor components in ACPs and a panel of 148 
other brain tumors and normal brain specimens including Pilocytic Astrocytomas (PAs), 
Atypical Teratoid/Rhabdoid Tumors (AT/RTs), Ependymomas (EPNs), Glioblastomas (GBMs), 
Gangliogliomas (GGs), Medulloblastomas (MEDs), and Embryonal Tumors (EmTs). Values are 
expressed as log2 gene expression. Horizontal red bars represent the mean, and error bars 
represent standard error of the mean (SEM) 
 
Figure 5: IDO-1 Gene Expression and immunohistochemistry. (a) Gene expression of IDO-1 in 
ACPs and a panel of 148 other brain tumors and normal brain specimens including Pilocytic 
Astrocytomas (PAs), Atypical Teratoid/Rhabdoid Tumors (AT/RTs), Ependymomas (EPNs), 
Glioblastomas (GBMs), Gangliogliomas (GGs), Medulloblastomas (MEDs), and Embryonal 
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Tumors (EmTs). Values are expressed as log2 gene expression. Horizontal red bars represent the 
mean, and error bars represent standard error of the mean (SEM) (b) immunohistochemical stain 
of normal frontal cortex using 4.16H1 anti-IDO-1 antibody. (c-f) immunohistochemical stains of 
ACP using 4.16H1 anti-IDO-1 antibody at 4x(c,e) and 20x(d,f) magnification 
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